Eur J Cancer. 2008 Jan;44(1):19-24. Epub 2007 Sep 24.

Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).

Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA.

Source

National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada.

Abstract

Oncology drug development has seen a paradigm shift in the past decade from traditional cytotoxic agents to molecular targeted therapies. Given the different mechanisms and toxicities of these agents, drug development methodology may also require novel approaches. To address emerging issues in oncology drug development the 'Methodology for the Development of Innovative Cancer Therapies' (MDICT) task force was established to provide a forum for academic leaders involved in cancer drug development to discuss methodological issues inherent to the study of targeted anticancer therapy. At the inaugural MDICT meeting in 2006, discussion focused on the most appropriate primary endpoints for first-in-man phase I studies of targeted anticancer agents and organisational issues of such studies. This report summarises the scientific reviews and discussions as well as the recommendations regarding phase I trial design formulated by the MDICT task force.

PMID:: 17890079; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Research Support, Non-U.S. Gov't

MeSH Terms

Substances

Antineoplastic Agents

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). [Eur J Cancer. 2008]
Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Eisenhauer EA, Seymour LK. Eur J Cancer. 2008 Jan; 44(1):25-9. Epub 2007 Sep 12.
Review Targeted agents: how to select the winners in preclinical and early clinical studies? [Eur J Cancer. 2012]
Review Targeted agents: how to select the winners in preclinical and early clinical studies?
Goodwin R, Giaccone G, Calvert H, Lobbezoo M, Eisenhauer EA. Eur J Cancer. 2012 Jan; 48(2):170-8. Epub 2011 Nov 15.
Review Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. [Eur J Cancer. 2009]
Review Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.
Kummar S, Doroshow JH, Tomaszewski JE, Calvert AH, Lobbezoo M, Giaccone G, Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer. 2009 Mar; 45(5):741-6. Epub 2008 Dec 16.
Review An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. [Clin Cancer Res. 2010]
Review An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
LoRusso PM, Boerner SA, Seymour L. Clin Cancer Res. 2010 Mar 15; 16(6):1710-8. Epub 2010 Mar 9.
[Future directions of anticancer drug development in Japan]. [Gan To Kagaku Ryoho. 2008]
[Future directions of anticancer drug development in Japan].
Akaza H, Kawai K, Tsuruo T, Tsukagoshi S, Aiba K, Shimada Y, Kakeji Y, Ishikawa H, Ikeda T, Nakamura S, et al. Gan To Kagaku Ryoho. 2008 Feb; 35(2):351-60.

See reviews... See all...

Cited by 8 PubMed Central articles

Phase 0 clinical trials in oncology new drug development. [Perspect Clin Res. 2011]
Phase 0 clinical trials in oncology new drug development.
Gupta UC, Bhatia S, Garg A, Sharma A, Choudhary V. Perspect Clin Res. 2011 Jan; 2(1):13-22.
Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials. [PLoS One. 2011]
Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials.
Ferte C, Soria JC, Penel N. PLoS One. 2011 Mar 2; 6(3):e16633. Epub 2011 Mar 2.
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. [Mol Cancer Ther. 2010]
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Quintela-Fandino M, Le Tourneau C, Duran I, Chen EX, Wang L, Tsao M, Bandarchi-Chamkhaleh B, Pham NA, Do T, MacLean M, et al. Mol Cancer Ther. 2010 Mar; 9(3):751-60. Epub 2010 Mar 2.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Endpoints and other considerations in phase I studies of targeted anticancer the...
Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
Eur J Cancer. 2008 Jan ;44(1):19-24. Epub 2007 Sep 24 .

PubMed
Niacin skin test response in dyslexia.
Niacin skin test response in dyslexia.
Prostaglandins Leukot Essent Fatty Acids. 2007 Aug ;77(2):123-8. Epub 2007 Sep 24 .

PubMed
Fatty acid composition of mature human milk in Nigeria.
Fatty acid composition of mature human milk in Nigeria.
Z Ernahrungswiss. 1991 Dec ;30(4):289-97.

PubMed
Influenza vaccines and vaccination strategies in birds.
Influenza vaccines and vaccination strategies in birds.
Comp Immunol Microbiol Infect Dis. 2008 Mar ;31(2-3):121-65. Epub 2007 Sep 24 .

PubMed
Pseudohypoaldosteronism: case report and discussion of the syndrome.
Pseudohypoaldosteronism: case report and discussion of the syndrome.
Yale J Biol Med. 1991 May-Jun ;64(3):247-54.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: